Palatin Technologies (PTN)
(Real Time Quote from BATS)
$1.27 USD
+0.06 (4.96%)
Updated Sep 24, 2024 10:10 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 1 - 20 ( 202 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Combo Obesity Study Doses First Patient; Topline Data Expected 1Q25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Combo Trial Ready to Rise to the Occasion; Topline Data Anticipated by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Palatin Kicks Off Combo Phase 2 Weight Loss Trial; Topline Data By YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q24 Results; Surge of Trial Initiations on the Horizon; PL9643 Type C Meeting with FDA Slated for 3Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Flexing the Issue: GLP-1 Agonists and the Quest for Balancing Weight Loss With Lean Muscle Preservation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Highlights How Dual MCR4/GLP-1 Agonism Could Do Heavy Lifting in Obesity
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MCR Agonists Not Willing to Fall Behind in the Obesity Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MELODY-1 Data Highlights From ASCRS 2024; Awaiting FDA Meeting in 2Q24 For Regulatory Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Does MELODY-1 Hit the Right Chord; We''ll See FDA Feedback; Target Lowered to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q24 Results; A Year of Catalysts, But Eyes Are Fixed on Imminent DED Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Bright Pipeline Outlook in 2024; Embracing a Wave of Upcoming Data Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
The Vyleesi Climax With Cash For the Effort; Focus on Phase 3 DED Data Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q24 Results; Looking For Sweet Music Shortly on Pivotal DED Study Read Out; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Uniting Melanocortin Receptor and GLP-1 Therapies For Obesity and Diabetes
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Further Bolster PL8177''s Potential in UC; Phase 2 UC Interim Data in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FY2023 Results; Pivotal DED Data Soon; Vyleesi Continues to Grow
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MELODY-1 Completes Enrollment; Top-Line Data in 4Q23 Represents Major Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Vyleesi Strengthens Foothold in Asian Marketplace; First China Sale and Phase 3 HSDD Enrollment Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J